RE: 2/3/2025 study utilising SRA7373 Apr 2025 20:21
This could be due to the stronger selectivity of SRA737 for CHK1 compared to prexasertib (1,000-fold greater selectivity)"
This stood out, great find. Surely any company using this for research of any sorts needs now sareum permission? Chk1 I find a mystery , as drug looks amazing , it's the momentum to take it forward